Total
0
Shares
Proteomics receives CE Mark for kidney disease test
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Proteomics has secured CE Mark registration for its kidney disease test, PromarkerD
  • Promarker D is a simple blood test that uses a uniques protein 'fingerprint' to detect the disease up to four years before clinical symptoms appear
  • This announcement follows the launch of PromarkerD in Spain, where diabetes affects 10 per cent of the adult population
  • Proteomics is up 1.49 per cent on the ASX and is selling shares for 34 cents apiece

Proteomics International Laboratories has secured CE Mark registration for its PromarkerD as a diagnostic medical device.

PromarkerD is a world-first test for predicting the beginning of diabetic kidney disease.

CE marking is a certification mark that indicates a fitting in with health, safety and environmental protection standards for products sold within the European Economic Area.

The test assesses the risk of diabetic kidney disease in patients with type 2 diabetes. Chronic kidney disease is one of the major complications that can come from diabetes and if unchecked can lead to dialysis or a kidney transplant.

Promarker D is a simple blood test that uses a unique protein 'fingerprint' to detect the disease up to four years before clinical symptoms appear.

"The CE Mark is another important milestone for PromarkerD as we move forward with new deals in the region," Managing Director Richard Lipscombe said.

"CE Mark registration reflects the strength of the clinical and technical data that we have collected in developing our ground-breaking test that could help save healthcare systems billions of dollars," he added.

This announcement follows the launch of PromarkerD in Spain, where diabetes affects 10 per cent of the adult population (3.6 million people).

The World Health Organisation believes that the European Region is home to 60 million adults with diabetes and currently 1 in 3 have chronic kidney disease.

"PromarkerD could aid clinical decision-making by identifying at-risk individuals for earlier therapeutic intervention and help to minimise the effect of the disease," the company stated.

Proteomics is up 1.49 per cent on the Australian Securities Exchange and is selling shares for 34 cents apiece at 12:55 pm AEDT.

PIQ by the numbers
More From The Market Herald
Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong (centre-left) - The Market Herald

" Imugene (ASX:IMU) increases loss, ramps up trials and research

Imugene (IMU) has ended the half-year with a $6 million loss after increasing its spending on clinical trials and research.
LBT Innovations (ASX:LBT) - CEO & Managing Director, Brent Barnes - The Market Herald

" LBT Innovations (ASX:LBT) pockets $830K R&D rebate

Medical technology player LBT Innovations (LBT) has pocketed $830,000 under a government research and development tax incentive.
Palla Pharma (ASX:PAL) - Departing CEO, Jarrod Ritchie - The Market Herald

" Palla Pharma (ASX:PAL) to raise $18M to reduce debt

Palla Pharma (PAL) has announced plans to tap investors and shareholders for an extra $18 million in capital via a fundraise.
Incannex Healthcare (ASX:IHL) - Chief Medical Officer, Dr Sud Agarwal (centre) - The Market Herald

" Incannex Healthcare (ASX:IHL) declares outstanding half-year revenue growth

Incannex Healthcare (IHL) has reported a revenue growth of 11,859 per cent to $1.23 million for the six months to December 31, 2020.